我们该往何处去？特应性皮炎发病机制中的复杂相互作用。
Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis.
机构信息
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Janssen Research and Development, Spring House, Pennsylvania, USA.
出版信息
J Invest Dermatol. 2021 Feb;141(2):274-284. doi: 10.1016/j.jid.2020.07.006. Epub 2020 Sep 15.
Abstract
Atopic dermatitis (AD) is a common, chronic, inflammatory skin condition characterized by recurrent and pruritic skin eruptions. Multiple factors contribute to the pathogenesis of AD, including skin barrier dysfunction, microbial dysbiosis, and immune dysregulation. Interactions among these factors form a complex, multidirectional network that can reinforce atopic skin disease but can also be ameliorated by targeted therapies. This review summarizes the complex interactions among contributing factors in AD and the implications on disease development and therapeutic interventions.
摘要
特应性皮炎（AD）是一种常见的慢性炎症性皮肤病，其特征是反复发作的瘙痒性皮疹。多种因素导致 AD 的发病机制，包括皮肤屏障功能障碍、微生物失调和免疫失调。这些因素之间的相互作用形成了一个复杂的、多向的网络，可以加重特应性皮肤病，但也可以通过靶向治疗来改善。本文综述了 AD 中致病因素之间的复杂相互作用及其对疾病发展和治疗干预的影响。
相似文献
1
Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis.我们该往何处去？特应性皮炎发病机制中的复杂相互作用。
J Invest Dermatol. 2021 Feb;141(2):274-284. doi: 10.1016/j.jid.2020.07.006. Epub 2020 Sep 15.
2
Effect of Staphylococcus aureus colonization and immune defects on the pathogenesis of atopic dermatitis.金黄色葡萄球菌定植和免疫缺陷对特应性皮炎发病机制的影响。
Arch Microbiol. 2024 Sep 20;206(10):410. doi: 10.1007/s00203-024-04134-w.
3
The Influence of Microbiome Dysbiosis and Bacterial Biofilms on Epidermal Barrier Function in Atopic Dermatitis-An Update.肠道菌群失调和细菌生物膜对特应性皮炎表皮屏障功能的影响——最新研究进展。
Int J Mol Sci. 2021 Aug 5;22(16):8403. doi: 10.3390/ijms22168403.
4
The Role of the Microbiota in the Pathogenesis and Treatment of Atopic Dermatitis-A Literature Review.肠道菌群在特应性皮炎发病机制和治疗中的作用——文献综述。
Int J Mol Sci. 2024 Jun 13;25(12):6539. doi: 10.3390/ijms25126539.
5
Atopic dermatitis: Pathophysiology, microbiota, and metabolome - A comprehensive review.特应性皮炎：病理生理学、微生物群和代谢组——全面综述。
Microbiol Res. 2024 Apr;281:127595. doi: 10.1016/j.micres.2023.127595. Epub 2024 Jan 3.
6
An Update on the Pathophysiology of Atopic Dermatitis.特应性皮炎病理生理学的最新进展
Dermatol Clin. 2017 Jul;35(3):317-326. doi: 10.1016/j.det.2017.02.006. Epub 2017 May 6.
7
Atopic dermatitis: pathogenesis.特应性皮炎：发病机制
Semin Cutan Med Surg. 2017 Sep;36(3):100-103. doi: 10.12788/j.sder.2017.036.
8
Pathophysiology of atopic dermatitis: Clinical implications.特应性皮炎的病理生理学：临床意义。
Allergy Asthma Proc. 2019 Mar 1;40(2):84-92. doi: 10.2500/aap.2019.40.4202.
9
The Interaction between the Host Genome, Epigenome, and the Gut-Skin Axis Microbiome in Atopic Dermatitis.特应性皮炎中宿主基因组、表观基因组与肠-皮轴微生物组的相互作用。
Int J Mol Sci. 2023 Sep 20;24(18):14322. doi: 10.3390/ijms241814322.
10
The role of skin dysbiosis in atopic dermatitis.皮肤微生态失调在特应性皮炎中的作用。
Eur J Dermatol. 2022 Jul 1;32(4):439-444. doi: 10.1684/ejd.2022.4289.
引用本文的文献
1
RNase 7 and Th cytokines synergistically increase the secretion of interleukin-6 from keratinocytes.核糖核酸酶7与Th细胞因子协同增加角质形成细胞白细胞介素-6的分泌。
Sci Rep. 2025 Jun 3;15(1):19396. doi: 10.1038/s41598-025-04403-8.
2
Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis.特应性皮炎与淋巴瘤风险：一项系统评价与荟萃分析。
Front Oncol. 2025 Apr 14;15:1580550. doi: 10.3389/fonc.2025.1580550. eCollection 2025.
3
Expression of an epidermal growth factor-transdermal peptide fusion protein in and its therapeutic effects on skin barrier repair.一种表皮生长因子-透皮肽融合蛋白在[具体对象未给出]中的表达及其对皮肤屏障修复的治疗作用。
Front Plant Sci. 2025 Apr 4;16:1573193. doi: 10.3389/fpls.2025.1573193. eCollection 2025.
4
Resolution of Chronic Inflammation, Restoration of Epigenetic Disturbances and Correction of Dysbiosis as an Adjunctive Approach to the Treatment of Atopic Dermatitis.慢性炎症的消退、表观遗传紊乱的恢复和微生态失调的纠正作为特应性皮炎治疗的辅助方法。
Cells. 2024 Nov 18;13(22):1899. doi: 10.3390/cells13221899.
5
Association between single nucleotide polymorphisms of interleukin-35 genes and atopic dermatitis.白细胞介素-35基因单核苷酸多态性与特应性皮炎之间的关联。
Postepy Dermatol Alergol. 2024 Aug;41(4):415-422. doi: 10.5114/ada.2024.141783. Epub 2024 Jul 25.
6
Schizonepeta tenuifolia Briq-Saposhnikovia divaricata decoction alleviates atopic dermatitis via downregulating macrophage TRPV1.荆防汤通过下调巨噬细胞TRPV1减轻特应性皮炎。
Front Pharmacol. 2024 Aug 27;15:1413513. doi: 10.3389/fphar.2024.1413513. eCollection 2024.
7
Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis.中重度特应性皮炎新旧系统治疗方法的比较。
Curr Allergy Asthma Rep. 2024 May;24(5):289-301. doi: 10.1007/s11882-024-01145-x. Epub 2024 Apr 18.
8
Skin repair and immunoregulatory effects of myeloid suppressor cells from human cord blood in atopic dermatitis.人脐血来源的髓系抑制细胞在特应性皮炎中的皮肤修复和免疫调节作用。
Front Immunol. 2024 Jan 9;14:1263646. doi: 10.3389/fimmu.2023.1263646. eCollection 2023.
9
Identification of potential miR‑155 target genes in epidermal immune microenvironment of atopic dermatitis patients and their inflammatory effects on HaCaT cells.特应性皮炎患者表皮免疫微环境中潜在miR-155靶基因的鉴定及其对HaCaT细胞的炎症影响。
Exp Ther Med. 2023 Nov 22;27(1):25. doi: 10.3892/etm.2023.12313. eCollection 2024 Jan.
10
Investigating dysregulation of TGF-β1/SMAD3 signaling in atopic dermatitis: a molecular and immunohistochemical analysis.探讨特应性皮炎中 TGF-β1/SMAD3 信号通路失调：分子和免疫组化分析。
Clin Exp Immunol. 2024 Apr 23;216(2):192-199. doi: 10.1093/cei/uxad130.
本文引用的文献
1
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.司库奇尤单抗靶向白细胞介素-17治疗特应性皮炎的2期随机双盲研究。
J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16.
2
Liquid-liquid phase separation drives skin barrier formation.液-液相分离驱动皮肤屏障的形成。
Science. 2020 Mar 13;367(6483). doi: 10.1126/science.aax9554.
3
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents.度普利尤单抗治疗儿童和青少年 2 型炎症性疾病。
Paediatr Drugs. 2020 Jun;22(3):295-310. doi: 10.1007/s40272-020-00387-2.
4
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.白细胞介素 13 高亲和力抑制剂 lebrikizumab 治疗成人中重度特应性皮炎的疗效和安全性：一项 2b 期随机临床试验。
JAMA Dermatol. 2020 Apr 1;156(4):411-420. doi: 10.1001/jamadermatol.2020.0079.
5
The Role of Th17-Related Cytokines in Atopic Dermatitis.Th17 相关细胞因子在特应性皮炎中的作用。
Int J Mol Sci. 2020 Feb 15;21(4):1314. doi: 10.3390/ijms21041314.
6
The Roles of Sex Hormones in the Course of Atopic Dermatitis.性荷尔蒙在特应性皮炎病程中的作用。
Int J Mol Sci. 2019 Sep 20;20(19):4660. doi: 10.3390/ijms20194660.
7
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.度普利尤单抗阻断白介素-4 受体α可减少特应性皮炎金黄色葡萄球菌定植并增加微生物多样性。
J Invest Dermatol. 2020 Jan;140(1):191-202.e7. doi: 10.1016/j.jid.2019.05.024. Epub 2019 Jun 25.
8
Quorum sensing between bacterial species on the skin protects against epidermal injury in atopic dermatitis.皮肤细菌种间群体感应可预防特应性皮炎的表皮损伤。
Sci Transl Med. 2019 May 1;11(490). doi: 10.1126/scitranslmed.aat8329.
9
The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.早期发病的儿童特应性皮炎的血液蛋白质组学特征显示全身性炎症，与成人长期疾病不同。
J Am Acad Dermatol. 2019 Aug;81(2):510-519. doi: 10.1016/j.jaad.2019.04.036. Epub 2019 Apr 19.
10
Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗后部分应答和非持久应答的管理建议。
Am J Clin Dermatol. 2019 Aug;20(4):565-569. doi: 10.1007/s40257-019-00436-8.
Zotero 插件